Can Tyco Healthcare Go It Alone?

There's little argument that over the past several years, Tyco International has emerged as a powerhouse in the hospital supply and medical device industries through aggressive deal-making and a creative leveraging strategy that has enabled it to increase profits even in price-sensitive markets. Now Tyco, under pressure from fall-out over the scandal engulfing Enron, is breaking up in an effort to restore investor confidence and value. Some time in the future, Tyco Healthcare will operate as a stand-alone company. Yet questions loom large as to how well Tyco's strategy will play with the investment community, with some industry executives believing Tyco Healthcare has more value broken-up than as a public company.

There's little argument that over the past several years, Tyco International Ltd. has emerged as a powerhouse in the hospital supply and medical device industries. Through aggressive deal-making—it has bought up several of its most important rivals in hospital supply—and a creative leveraging strategy that has enabled it to increase profits even in price-sensitive markets, Tyco has been the 800-pound gorilla in medical supply. (See "What Makes Tyco Run?" IN VIVO, March 1999 [A#1999800050.) Moreover, as the leading force in hospital supply consolidation, its growth has come virtually at everyone else's expense. As it has gobbled up one competitor after another, it seems, the bigger Tyco has grown, the smaller everyone else has gotten, in both absolute and relative terms.

For the past several years, Tyco Healthcare Group LP has been one of Tyco's best performing businesses, but it has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.